Hemostatic variables and ischemic cardiovascular disease: do we need a concerted effort for more profitable future clinical investigations?
Abnormally high levels of some hemostatic variables are often associated with the occurrence of the major ischemic complications of atherosclerosis, myocardial infarction, and stroke. Intervention studies have shown that prolonged treatment with antiplatelet drugs significantly reduces the recurrence of coronary and cerebral ischemic episodes. The association of the ischemic event with the hemostatic abnormality has often been just descriptive. Although suggestive, the link between the abnormality and the development and progression of atherosclerosis is only circumstantial. Finally, no information is available on the presence of one or more abnormal variables in subjects who did or did not experience a recurrence of thrombosis with treatment. To strengthen the clinical relevance of these hemostatic variables and to maximize the effectiveness of antithrombotic strategies, these indices should be taken into account in studies evaluating nonpharmacological and pharmacological interventions against arterial thrombosis. We believe that a task force on this subject would serve a useful purpose. The task force should develop and publicize within the cardiological community guidelines for (a) defining the size of the problem, (b) identifying the variables to measure, (c) standardizing detection and monitoring techniques, and (d) suggesting appropriate strategies of prevention and treatment.